Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

Executive Summary

NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21

Related Content

In 2012, Pfizer’s Deal-Makers Seek Strategic Fit, Financial Discipline, Collaborative Risk-Sharing
Abbott Shaves U.S. Pharma Costs With Restructuring
More Deal Of The Year Nominees
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
Ten Months On, Abbott, Wockhardt Terminate Deal For Nutritional Business
Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
Daiichi Sankyo Assumes Complete Control Of Ranbaxy, As Founders Exit





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts